Previsioni

Il prezzo obiettivo medio degli analisti è +16,31€ (−4,51%). La mediana è +16,31€ (−4,51%).

Acquista	8
Mantieni	4
Vendi	0

Notizie Vai al feed delle notizie

Schrödinger beats Q2 2026 forecasts and returns to profitability

Schrödinger reported an adjusted Q2 2026 EPS of $0.08 versus an expected -$0.49 and revenue of $58.9 million versus an estimated $48.08 million. Annual contract value (ACV) rose 27% to $29.6 million, and the hosted software model accounted for 47% of software revenue. The company raised its full-year guidance for the drug discovery business to $65–75 million after a $10 million milestone payment from Ajax. The stock rose after the results, and Schrödinger emphasized long-term growth potential from new products like Bunsen and Predictive Tox despite near-term margin pressure. » Altro su de.investing.com
Schrödinger delivers Bunsen AI to Bristol Myers Squibb to accelerate drug discovery

Schrödinger and Bristol Myers Squibb are expanding their partnership: BMS will use Schrödinger’s AI platform Bunsen together with the computational platform and the synthesis‑planning software RetroSynth in research. Schrödinger is working with BMS scientists to further develop Bunsen for large‑scale chemical exploration and the integration of physics‑based calculations. The goal is to plan, execute and interpret workflows in molecular research to speed up the discovery of new drugs. » Altro su de.investing.com
Schrödinger introduces AI‑powered co‑scientist Bunsen in early access

Schrödinger has unveiled the early‑access version of Bunsen, an agent‑based AI system that combines AI with physics‑based simulations for molecular drug discovery. Bunsen helps researchers understand scientific goals via natural language, develop computational strategies, orchestrate workflows on the Schrödinger platform, and interpret calculation results. NVIDIA and Google Cloud provide the underlying compute infrastructure and integration; commercial launch is planned by the end of 2026. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Schrödinger ha registrato ricavi pari a 51,60M€ e un utile netto di 5,24M€

(EUR)	giu 2026	YoY
Ricavi	+51,60M	11,06%
Utile lordo	+28,42M	28,05%
Utile netto	+5,24M	114,29%
EBITDA	+6,44M	118,35%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1,28Mld€
Numero di azioni	74,72M
Massimo/minimo a 52 settimane	+19,77€ - +9,40€
Dividendi	No
Beta	1,66
Rapporto P/E	−27,01
Rapporto PEG	−0,23
Rapporto P/B	+4,54
Rapporto P/S	+5,77

Profilo aziendale

Schrödinger, Inc. bietet zusammen mit seinen Tochtergesellschaften eine auf Physik basierende Softwareplattform an, die die Entdeckung neuartiger Moleküle für die Arzneimittelentwicklung und Materialanwendungen ermöglicht. Das Unternehmen ist in zwei Segmenten tätig: Software und Drug Discovery. Das Software-Segment konzentriert sich auf den Verkauf seiner Software für die Arzneimittelforschung in der Life-Science-Industrie sowie an Kunden in der materialwissenschaftlichen Industrie. Das Segment Drug Discovery konzentriert sich auf den Aufbau eines Portfolios von präklinischen und klinischen Programmen, sowohl intern als auch durch Kooperationen. Das Unternehmen beliefert biopharmazeutische und industrielle Unternehmen, akademische Einrichtungen und staatliche Labors weltweit. Schrödinger, Inc. wurde 1990 gegründet und hat seinen Sitz in New York, New York.

Nome	Schrödinger
CEO	Ramy Farid
Sede centrale	New York, ny Stati Uniti
Sito web	schrodinger.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	06/02/2020
Dipendenti	850